Investor Relations

2016 News Releases

Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012
DateTitle  
11/17/16Millendo Therapeutics Announces Appointment of Christopher J. Seiter as Chief Financial Officer
... 
Printer Friendly Version
11/03/16Millendo Therapeutics Announces Data Presentations at Androgen Excess and Polycystic Ovary Syndrome Society Annual Meeting
... 
Printer Friendly Version
11/02/16Millendo Therapeutics Announces Data Presentations at Society for Endocrinology British Endocrine Societies Conference
... 
Printer Friendly Version
10/13/16Millendo Therapeutics Announces Appointment of Three Vice Presidents
... 
Printer Friendly Version
08/16/16Millendo Therapeutics Announces Initiation of Phase 2b Clinical Trial of MLE4901 in Patients with Polycystic Ovary Syndrome
... 
Printer Friendly Version
07/27/16Millendo Therapeutics Announces Publication of Positive Phase 2a Data for MLE4901 for the Treatment of Polycystic Ovary Syndrome
... 
Printer Friendly Version
06/23/16Millendo Therapeutics Appoints New Independent Board Member and Names Chairperson of the Board
... 
Printer Friendly Version
06/08/16Millendo Therapeutics Announces Initiation of Phase 2 Clinical Trial of ATR-101 in Patients with Congenital Adrenal Hyperplasia
... 
Printer Friendly Version
06/01/16Millendo Therapeutics to Present at the Jefferies 2016 Healthcare Conference
... 
Printer Friendly Version
04/14/16Millendo Therapeutics Expands Management Team with Addition of Two Vice Presidents
... 
Printer Friendly Version
03/18/16Millendo Therapeutics Announces Publication of Preclinical Data for ATR-101 and Data Presentations at ENDO 2016
... 
Printer Friendly Version
02/02/16Millendo Therapeutics to Present at Four Upcoming Conferences
... 
Printer Friendly Version
01/05/16Millendo Licenses Phase 2 Polycystic Ovary Syndrome (PCOS) Drug Candidate from AstraZeneca and Secures Series B Financing of $62 Million to Advance Pipeline of Endocrine Disorder Therapies
... 
Printer Friendly Version
01/05/16FierceBiotech: Ann Arbor biotech upstart grabs $62M round and a PhII drug from AstraZeneca
... 
Printer Friendly Version
01/05/16Xconomy: Formerly Atterocor, Millendo Changes Name, Strategy—And Nabs $62M
... 
Printer Friendly Version